SERS-based immunoassay using gold-patterned array chips for rapid and sensitive detection of dual cardiac biomarkers

Cheng, Ziyi; Wang, Rui; Xing, Yanlong; Zhao, Linlu; Choo, Jaebum; Yu, Fabiao

doi:10.1039/c9an01260e

Cited by 52 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GO/AuNP complexes provided strong SERS enhancement ability and detected cTnI with a 5 pg/mL detection limit (Fu et al, 2019). Similarly, Cheng et al (2019) loaded targets and polyclonal-antibody-conjugated Au@Ag core-shell nanoparticles in a gold-patterned chip that ran as a SERS active template for the ultrasensitive detection of cTnI and CK-MB. The limits of detection were 8.9 pg/mL and 9.7 pg/mL for cTnI and CK-MB, respectively.…”

Section: Surface-enhanced Raman Scattering (Sers)mentioning

confidence: 99%

Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases

Shi

Yang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are the leading cause of death and morbidity in the world and are a major contributor to healthcare costs. Although enormous progress has been made in diagnosing CVD, there is an urgent need for more efficient early detection and the development of novel diagnostic tools. Currently, CVD diagnosis relies primarily on clinical symptoms based on molecular imaging (MOI) or biomarkers associated with CVDs. However, sensitivity, specificity, and accuracy of the assay are still challenging for early-stage CVDs. Nanomaterial platform has been identified as a promising candidate for improving the practical usage of diagnostic tools because of their unique physicochemical properties. In this review article, we introduced cardiac biomarkers and imaging techniques that are currently used for CVD diagnosis. We presented the applications of various nanotechnologies on diagnosis within cardiac immunoassays (CIAs) and molecular imaging. We also summarized and compared different cardiac immunoassays based on their sensitivities and working ranges of biomarkers.

show abstract

Section: Surface-enhanced Raman Scattering (Sers)mentioning

confidence: 99%

Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases

Shi

Yang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Cardiac troponin I proteins (cTnIs) have been regarded as specific biomarkers for AMI because cTnIs are released only when myocardial tissues are damaged [1,3]. Therefore, diverse methods have been developed for the sensitive and specific sensing of cTnIs [4][5][6][7][8][9][10][11][12][13][14][15][16]. Typically, cTnIs have been identified by radioimmunoassay and enzyme-linked immunosorbent assay (ELSIA) [6,7].…”

Section: Introductionmentioning

confidence: 99%

“…However, these methods often suffer from limitations such as low sensitivity, poor stability, and the high cost of antibodies. Although several approaches have been recently developed for AMI biomarkers [8][9][10][11][12][13][14][15][16], there is still a need to improve sensing performance for detecting very low levels of cTnIs.…”

Section: Introductionmentioning

confidence: 99%

Troponin Aptamer on an Atomically Flat Au Nanoplate Platform for Detection of Cardiac Troponin I

et al. 2020

View full text Add to dashboard Cite

Well-ordered bioreceptors on atomically flat Au surfaces can be a high-performance biosensor. Cardiac troponin I proteins (cTnIs) have been regarded as a specific biomarker for acute myocardial infarction (AMI). Here, we report the accurate detection of cTnIs using an aptamer-immobilized Au nanoplate platform. The single-crystalline and atomically flat Au nanoplate was characterized by atomic force microscopy. For the precise detection of cTnI, we immobilized an aptamer that can strongly bind to cTnI onto an atomically flat Au nanoplate. Using the aptamer-immobilized Au nanoplate, cTnIs were successfully detected at a concentration of 100 aM (2.4 fg/mL) in buffer solution. Furthermore, cTnIs in serum could be identified at a concentration of 100 fM (2.4 pg/mL). The total assay time was ~7 h. Importantly, the aptamer-immobilized Au nanoplate enabled us to diagnose AMI patients accurately, suggesting the potential of the present method in the diagnosis of AMI.

show abstract

“…Currently, various methods are available for the detection of cTnI, such as chemiluminescence, luorescence,electrochemical immunoassay and surface-enhanced Raman scattering (SERS)-based sandwich immunoassay platform [16][17][18]. However, chemiluminescence immunoassay requires complex operations, large expenses and time consumption, while luorescence immunoassay is bulky, expensive and requires trained personnel to perform the tests.…”

Section: Introductionmentioning

confidence: 99%

Peptide-based antifouling aptasensor for cardiac troponin I detection by surface plasmon resonance applied in medium sized Myocardial Infarction

Jia¹,

Wu²,

Chang³

et al. 2020

Ann Biomed Sci Eng

View full text Add to dashboard Cite

show abstract

SERS-based immunoassay using gold-patterned array chips for rapid and sensitive detection of dual cardiac biomarkers

Abstract: A gold-patterned array platform has been developed for the ultrasensitive SERS-based detection of cTnI and CK-MB.

Cited by 52 publications

References 32 publications

Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases

Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases

Troponin Aptamer on an Atomically Flat Au Nanoplate Platform for Detection of Cardiac Troponin I

Peptide-based antifouling aptasensor for cardiac troponin I detection by surface plasmon resonance applied in medium sized Myocardial Infarction

Contact Info

Product

Resources

About